EMA statement on ongoing review of GLP-1 receptor agonists

July 11, 2023

In response to an ongoing review, the European Medicines Agency (EMA) has issued a statement regarding GLP-1 receptor agonists. These medications are commonly used in the treatment of type 2 diabetes. The review is being conducted to assess the potential risk of pancreatic adverse events associated with the use of GLP-1 receptor agonists.

The EMA highlights the importance of balancing the benefits and risks of these medications and emphasizes that patients should continue to follow their prescribed treatment until further information is available.

The EMA reassures healthcare professionals and patients that they are actively monitoring the situation and will provide updates as necessary, ensuring the safety and well-being of individuals receiving GLP-1 receptor agonist therapy.


Get In Touch

We value your input and always appreciate feedback. Your suggestions and comments help us improve our services, ensuring that we consistently meet your needs and exceed your expectations.

Thank you we will get back to you shortly!

MO - FR 9:00 am - 5:00 pm

+ 420 774 557 550


Czech Republic,
Nile House, Karolinská 654/2, Karlín, 186 00, Prague